SC rejects plea for CBI probe into cough syrup deaths

Published On 2025-10-11 06:30 GMT | Update On 2025-10-11 06:30 GMT

Supreme Court of India

In a swift legal action, the Supreme Court of India dismissed a Public Interest Litigation (PIL) demanding an inquiry and systemic reform in drug safety mechanisms following the tragic deaths of children in Madhya Pradesh and Rajasthan, allegedly due to the consumption of toxic cough syrups.

The PIL, filed by lawyer Vishal Tiwari, sought urgent intervention into the matter.

A bench comprising Chief Justice B R Gavai and Justices Ujjal Bhuyan and K Vinod Chandran dismissed the PIL after Solicitor General Tushar Mehta objected to it.

As per PTI, the top law officer said the petitioner reads the newspaper and rushes to the court.

The bench, which was initially of the view that the notice should be issued, later dismissed it.

Mehta said he was not appearing for any state at the moment but the seriousness with which states like Tamil Nadu and Madhya Pradesh are taking actions cannot be undermined.

Moreover, there are proper law enforcement mechanisms in states, he added.

The bench asked Tiwari as to how many PILs he has filed so far in the top court and on being told that he has moved eight to 10 such pleas so far, the bench dismissed the instant petition.

"Dismissed," the CJI said.

The PIL claimed that laboratory tests conducted by the Madhya Pradesh government confirmed that Diethylene Glycol (DEG)—a toxic industrial solvent prohibited for pharmaceutical use—was found in 'Coldrif Cough Syrup', manufactured by Tamil Nadu's Sresan Pharma Pvt. Ltd.

“Despite the catastrophic findings, the Union Government and the Central Drugs Standard Control Organisation (CDSCO) allegedly failed to issue an immediate nationwide recall or ban, permitting the continued circulation of potentially poisonous medicines across States,” the plea stated.

“This is not a tragedy of chance but of negligence, apathy, and regulatory failure -- an institutional rot that allows counterfeit and adulterated drugs to enter the public market unchecked,” the PIL stated.

Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

SC rejects plea for CBI probe into cough syrup deaths

Similar News

Contaminated Cough syrup tragedy: Sresen Pharma owner remanded in 10-day police custody

CDSCO Panel Seeks More Safety Data from Raptim Research on Lenalidomide Patch

USFDA concludes inspection at Emcure Pharma Gujarat facility without any observation

AstraZeneca Gets SEC Nod for New Trastuzumab Deruxtecan Indication in HER2-Positive Solid Tumors

No Entry Without Notice: CDSCO Directs All Drug Shipments Through Notified Ports via ICEGATE

Lupin Launches Strategic Partnership to Expand PrecisionSphere Long-Acting Injectable Platform

Chemist Loses Rs 1.01 Crore in Social Media Investment Scam